Although genetic alterations in tumor suppressor genes TP53 and CDKN2A are common in HNSCC, these alterations are notoriously difficult to exploit for targeted therapeutics at present. The gene discussed is CDKN2A; the disease is head and neck squamous cell carcinoma.